Cite
Yamada K, Nakayama H, Yoshinobu S, et al. Effects of a sodium glucose co-transporter 2 selective inhibitor, ipragliflozin, on the diurnal profile of plasma glucose in patients with type 2 diabetes: A study using continuous glucose monitoring. J Diabetes Investig. 2015;6(6):699-707doi: 10.1111/jdi.12370.
Yamada, K., Nakayama, H., Yoshinobu, S., Kawano, S., Tsuruta, M., Nohara, M., Hasuo, R., Akasu, S., Tokubuchi, I., Wada, N., Hirao, S., Iwata, S., Kaku, H., & Tajiri, Y. (2015). Effects of a sodium glucose co-transporter 2 selective inhibitor, ipragliflozin, on the diurnal profile of plasma glucose in patients with type 2 diabetes: A study using continuous glucose monitoring. Journal of diabetes investigation, 6(6), 699-707. https://doi.org/10.1111/jdi.12370
Yamada, Kentaro, et al. "Effects of a sodium glucose co-transporter 2 selective inhibitor, ipragliflozin, on the diurnal profile of plasma glucose in patients with type 2 diabetes: A study using continuous glucose monitoring." Journal of diabetes investigation vol. 6,6 (2015): 699-707. doi: https://doi.org/10.1111/jdi.12370
Yamada K, Nakayama H, Yoshinobu S, Kawano S, Tsuruta M, Nohara M, Hasuo R, Akasu S, Tokubuchi I, Wada N, Hirao S, Iwata S, Kaku H, Tajiri Y. Effects of a sodium glucose co-transporter 2 selective inhibitor, ipragliflozin, on the diurnal profile of plasma glucose in patients with type 2 diabetes: A study using continuous glucose monitoring. J Diabetes Investig. 2015 Nov;6(6):699-707. doi: 10.1111/jdi.12370. Epub 2015 Jun 20. PMID: 26543545; PMCID: PMC4627548.
Copy
Download .nbib